检索临床试验

这项首次人体研究将评估安全性, 耐受性, 药物动力学, TORL-4-500在晚期肿瘤患者中的抗肿瘤活性

这项首次人体研究将评估安全性, 耐受性, 药物动力学, TORL-3-600在晚期肿瘤患者中的抗肿瘤活性

这项研究正在研究一种新的化合物, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

这是人类首次(FIH) I/II期, 跨国公司, 多中心, HB-201单载体治疗与HB-201的开放标签研究 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and 耐受性 of DB-1305/BNT325 in subjects with advanced solid tumors.

这是第一次人体试验, 阶段1 b / 1, 多中心, 非盲, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

IMGN151-1001是一期产品, 首先是人类, 非盲 dose-escalation and expansion study in adult patients with 复发性 endometrial cancer, 复发性, 卵巢高级别浆液上皮, 原发性腹膜, 或者输卵管癌.

来描述安全性, 耐受性, 药物动力学, 药效学, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, 食管鳞癌, 肾细胞癌, and human papilloma virus associated head and neck squamous cell carcinoma.

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer

这项首次人体研究将评估安全性, 耐受性, 药物动力学, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

This is a phase 1 study to assess the safety and 耐受性 of ARX517 in adult subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

这是第一阶段, 非盲, 随访时间, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, 在标准治疗后是否有疾病进展, 或者之前其他治疗失败. 这项研究分为两个阶段. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. 单克隆抗体免疫治疗, 比如派姆单抗, 能帮助人体免疫系统攻击癌症吗, 并可能干扰肿瘤细胞生长和扩散的能力.

1/2期开放标签, 安全性的多中心研究, 药物动力学, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. 因为一些癌症占用了68Ga-FAPi-46，可以通过PET看到. FAP代表成纤维细胞活化蛋白. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

To evaluate the safety and 耐受性 of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C突变体晚期实体瘤.